Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

Two phase II studies of S-1 monotherapy have shown promising response rates (RR) of 35–40% with good tolerability in patients with untreated metastatic colorectal cancer. To investigate the usefulness of S-1 plus oxaliplatin (SOX) as an alternative to infusional 5-fluorouracil/leucovorin plus oxalip...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Y, Tahara, M, Miya, T, Satoh, T, Shirao, K, Shimada, Y, Ohtsu, A, Sasaki, Y, Tanigawara, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275487/
https://www.ncbi.nlm.nih.gov/pubmed/18319719
http://dx.doi.org/10.1038/sj.bjc.6604271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275487/
https://www.ncbi.nlm.nih.gov/pubmed/18319719
http://dx.doi.org/10.1038/sj.bjc.6604271

Ejemplares similares